Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.
作者信息
Sahoo Suman, Pandey Abhishek, Mandal Swarnendu, Kumar Das Manoj, Nayak Prasant
机构信息
Department of Urology, All India Institute of Medical Sciences-Bhubaneswar, Bhubaneswar, India.
Department of Urology, All India Institute of Medical Sciences-Bhubaneswar, Bhubaneswar, India.
出版信息
Eur Urol. 2023 Feb;83(2):e47. doi: 10.1016/j.eururo.2022.10.027. Epub 2022 Nov 17.
PMID:36404203
Abstract
摘要
相似文献
1
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.回复：沈伟、亚伦·普伦德加斯特、夏洛特·阿克曼等。中危非肌层浸润性膀胱癌患者辅助膀胱内热化疗与单纯化疗的比较（HIVEC-II）：一项2期、开放标签、随机对照试验。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2022.08.003
Eur Urol. 2023 Feb;83(2):e47. doi: 10.1016/j.eururo.2022.10.027. Epub 2022 Nov 17.
2
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackermann, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.回复：沈伟、亚伦·普伦德加斯特、夏洛特·阿克曼等人。中危非肌层浸润性膀胱癌患者辅助膀胱内热化疗与单纯化疗的比较（HIVEC-II）：一项2期开放标签随机对照试验。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2022.08.003
Eur Urol. 2023 Feb;83(2):e56-e57. doi: 10.1016/j.eururo.2022.09.035. Epub 2022 Nov 10.
3
Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.回复苏曼·萨胡、阿比谢克·潘迪、斯瓦伦杜·曼达尔、马诺伊·库马尔·达斯和普拉萨特·纳亚克致编辑的信，信的内容涉及魏申·谭、亚伦·彭德加斯特、夏洛特·阿克曼等人的《中危非肌层浸润性膀胱癌患者辅助膀胱内热化疗与单纯化疗的对比（HIVEC-II）：一项2期、开放标签、随机对照试验》。《欧洲泌尿外科杂志》待发表。https://doi.org/10.1016/j.eururo.2022.08.003 。
Eur Urol. 2023 Feb;83(2):e48-e49. doi: 10.1016/j.eururo.2022.11.006. Epub 2022 Nov 28.
4
Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.回复法比奥·坎波多尼科、弗朗西斯卡·马蒂奥利和卡洛·因托里尼致编辑的信，信的内容涉及：魏申·谭、亚伦·彭德加斯特、夏洛特·阿克曼等人。中危非肌层浸润性膀胱癌患者的膀胱内热化疗与单纯化疗对比研究（HIVEC-II）：一项2期开放标签随机对照试验。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2022.08.003 。
Eur Urol. 2023 Jan;83(1):e29-e30. doi: 10.1016/j.eururo.2022.10.009. Epub 2022 Oct 20.
5
Re: Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.回复：中危非肌层浸润性膀胱癌患者辅助膀胱内热化疗与单纯化疗对比研究（HIVEC-II）：一项2期开放标签随机对照试验
Eur Urol. 2023 Jun;83(6):580. doi: 10.1016/j.eururo.2023.01.008. Epub 2023 Jan 27.
6
Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial.辅助性膀胱内化疗热疗与中危非肌肉浸润性膀胱癌患者的被动化疗（HIVEC-II）：一项 2 期、开放标签、随机对照试验。
Eur Urol. 2023 Jun;83(6):497-504. doi: 10.1016/j.eururo.2022.08.003. Epub 2022 Aug 20.
7
Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52.回复：汤姆·J.H.·阿伦兹、奥费·纳蒂夫、马西莫·马费齐尼等。一项随机对照试验的结果：比较膀胱内热化疗联合丝裂霉素C与卡介苗对中高危非肌层浸润性膀胱癌患者的辅助治疗。《欧洲泌尿外科杂志》2016年；69卷：1046 - 52页
Eur Urol. 2019 Feb;75(2):e25. doi: 10.1016/j.eururo.2018.08.046. Epub 2018 Sep 17.
8
Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52.回复：汤姆·J.H.·阿伦兹、奥费·纳蒂夫、马西莫·马费齐尼等。一项比较膀胱内热化疗联合丝裂霉素C与卡介苗辅助治疗中高危非肌层浸润性膀胱癌患者的随机对照试验结果。《欧洲泌尿外科杂志》2016年；69卷：1046 - 52页。
Eur Urol. 2017 Jan;71(1):e29-e30. doi: 10.1016/j.eururo.2016.06.042. Epub 2016 Jul 11.
9
Reply to Harshit Garg, Brusabhanu Nayak and Prabhjot Singh's Letter to the Editor Re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guerin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52.回复哈什特·加尔格、布鲁萨巴胡努·纳亚克和普拉布乔特·辛格致编辑的信：关于汤姆·J.H. 阿伦兹、奥费·纳蒂夫、马西莫·马费齐尼等人。一项随机对照试验的结果，比较膀胱内热化疗联合丝裂霉素C与卡介苗用于中高危非肌层浸润性膀胱癌患者辅助治疗的疗效。《欧洲泌尿外科杂志》2016年；69:1046 - 52。
Eur Urol. 2019 Feb;75(2):e26. doi: 10.1016/j.eururo.2018.08.045. Epub 2018 Sep 26.
10
Reply to Sławomir Poletajew, Piotr Radziszewski, Juan Palou's Letter to the Editor re: Tom J.H. Arends, Ofer Nativ, Massimo Maffezzini, et al. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. Eur Urol 2016;69:1046-52.回复斯拉沃米尔·波莱塔耶夫、彼得·拉齐谢夫斯基、胡安·帕洛致编辑的信：关于汤姆·J.H. 阿伦兹、奥费·纳蒂夫、马西莫·马费齐尼等人的“一项比较膀胱内热化疗联合丝裂霉素C与卡介苗辅助治疗中高危非肌层浸润性膀胱癌患者的随机对照试验结果”。《欧洲泌尿外科杂志》2016年；69卷：1046 - 52页
Eur Urol. 2017 Jan;71(1):e31-e32. doi: 10.1016/j.eururo.2016.06.043. Epub 2016 Jul 15.
Zotero 插件